Appointment to Clinical Advis

RNS Number : 5404Z

Surgical Innovations Group PLC

17 January 2011

 



News release

17 January 2011

Surgical Innovations Group plc

("SI" or "the Group")

Appointments to the Clinical Advisory Board

Surgical Innovations Group plc (AIM:SUN), the designer and manufacturer of innovative medical devices, is pleased to announce the appointment of arthroscopic specialist Mr Jon Conroy and laparoscopic specialist Mr Marco Adamo to its Clinical Advisory Board (CAB) with immediate effect.

Mr Jon Conroy, BSc, MB ChB, FRCS (Eng), FRCS (Tr & Orth), MSc, is a Consultant Orthopaedic Surgeon specialising in joint replacements and arthropscopic, or 'keyhole', surgeries to the hip and knee.  Mr Conroy is a member of the British Hip Society, International Society of Hip Arthroscopy, The British Orthopaedic Association and a Fellow of The Royal College of Surgeons of England.  He also holds a master's degree in Mechanical Engineering from Leeds University.  Mr Conroy has published research in several medical journals and won the GlaxoSmithKlein Orthopaedic Essay Prize in 2005 and the John Fitton Prize for Orthopaedic Specialist Registrars in 2006. 

Mr Marco Adamo, MD is a Consultant Surgeon and Bariatric Surgery Lead at the University College London Hospital (UCLH) where he has worked since 2007.  He graduated in 1995 with full marks and honours in Palermo, Italy, where he also completed his training in general surgery.  Since moving to the UK in 2000 he has focused on advanced laparoscopic surgery and laparoscopic bariatric (obesity) surgery.  He performed the first single incision laparoscopic sleeve gastrectomy in the UK and also has a specific interest in laparoscopic hernia surgery.  As a dedicated trainer in his field he often runs advanced training courses for UK and European surgeons.  Mr Adamo is a member of the European Association of Endoscopic Surgery (EAES), British Society for Metabolic and Obesity Surgery (BOMSS), Association of Upper-GI Surgeons (AUGIS) and Association of Laparoscopic Surgeons in UK (ALS) and Italy (SICE). 

Graham Bowland, Chief Executive Officer for Surgical Innovations, said: "We are very pleased to welcome Jon and Marco to the CAB.  Jon's expertise in arthroscopy will be invaluable as we begin to develop minimally invasive surgical devices for this very important market.  Marco's appointment will strengthen our specialist bariatric team and significantly add value to the development of devices for this particular area of surgery.  Our CAB now consists of nine highly experienced surgeons covering a wide range of specialism and markets."

Enquiries:

Surgical Innovations Group plc

Doug Liversidge, Chairman

Graham Bowland, Chief Executive Officer                                    Tel: [phone]

[e-mail]                                                           www.surginno.com

Seymour Pierce Limited

Freddy Crossley / Sarah Jacobs                                                     Tel: [phone]

Corporate Broking

Marianne Woods                                                                            www.seymourpierce.com

Media enquiries:

The Communications Portfolio

Ariane Comstive                                                                            Tel: [phone]

[e-mail]                    Mob: [phone]

Notes to Editors:

About Surgical Innovations Group plc

Surgical Innovations Group plc specialises in the design and manufacture of innovative devices for use in minimally invasive surgery (MIS) and industrial markets. 

As well as manufacturing single-use and reusable instruments for the laparoscopic market, the Group has pioneered its flagship Resposable® instrumentation combining both single use and reusable components, ensuring ongoing revenue streams and delivering the optimum procedure performance to cost ratio.

Over 100 people are employed at the Group's 32,000 square feet facility in Leeds, with in-house design, plastic injection moulding and manufacturing equipment, producing products to the highest quality standards.

The Group's patented products are sold through three main channels:

SI brand	Through an established network of 45 distribution partners, Surgical Innovations branded products are sold in all major medical markets including North America, Europe, South Africa, the Middle East, South-east Asia and Australia.
OEM and IP	The Group supplies large medical device companies on an OEM basis, collecting sales fees as well as IP license and royalty fees.  Clients include Teleflex Medical, Gyrus and CareFusion.
Industrial	SI's patented segment technology has been applied to the industrial market enabling customers to undertake inspection and maintenance of large-scale equipment, such as turbines, in situ with minimum disassembly and downtime.

For more information, see www.surginno.com

 

END

 

 

NRAGGUWAGUPGGBC